** Shares of drug developer Tevogen Bio rise as much as 84.5% to an over six-month high of $2.97
** Co says its artificial intelligence effort, Tevogen AI, has partnered with Microsoft under Microsoft for Startups program
** TVGN says the partnership will provide it with access to MSFT's extensive ecosystem
** "The partnership is set to accelerate and streamline the development of Tevogen’s proprietary algorithms, significantly advancing our mission to lower the total cost of drug development, expedite drug discovery" - co
** According to McKinsey Global Institute, generative AI could generate $60 bln-$110 bln annually in economic value for pharma and medtech companies, with $18-$30 billion of that value attributed to commercial functions alone - TVGN
** Tevogen AI's chief information officer, Mittul Mehta, used to work at MSFT
** YTD, TVGN stock down 78%
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。